Aurobindo Pharma Ltd

Analyst / Investor Meet - Intimation

Intimation of Investor/ Analyst meet scheduled on September 1, 2026.

Company Update / Analyst / Investor Meet View filing →

Analyst / Investor Meet - Intimation

Intimation of Participation in Investor/ Analyst meet held on September 1-2, 2026 in Hong Kong

Company Update / Analyst / Investor Meet View filing →

Completion Of US FDA Inspection At Lannett Company LLC, A Wholly Owned Subsidiary Of Aurobindo Pharma USA, Inc.

Intimation of completion of US FDA inspection at Lannett Company LLC., a wholly owned subsidiary of Aurobindo Pharma, USA Inc.

Company Update / General View filing →

Completion Of US FDA Inspection At Auro Peptides Ltd, A Subsidiary/Business Arm Of The Company.

Intimation of completion of US FDA inspection at Auro Peptides Limited, a subsidiary of the Company.

Company Update / General View filing →

Classification Of US FDA Inspection At Raleigh Plant, North Carolina, Owned By Aurolife Pharma LLC, A Wholly Owned Step-Down Subsidiary Of The Company, As Voluntary Action Indicated (VAI)

Intimation of classification of US FDA inspection at Raleigh Plant, North Carolina, owned by Aurolife LLF, a wholly owned step down subsidiary of the Company, as Voluntary Actioin Indicated (VAI).

Company Update / General View filing →

Unit I Of Eugia Pharma Specialities Ltd. Received A Warning Letter From US FDA

Intimation of receipt of warning letter from US FDA by Unit 1 of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.

Company Update / General View filing →

Analyst / Investor Meet - Intimation

Intimation of participation of officials of the Company in investors / analysts meet to be held on August 19, 2026

Company Update / Analyst / Investor Meet View filing →

Newspaper Publication

Submission of copies of newspaper advertisements of the financial results of the Company for the first quarter ended June 30, 2026 as published in Business Standard and Nava Telangana on ....

Company Update / Newspaper Publication View filing →

Newspaper Publication

Submission of copies of notice published by the Company on August 7, 2026 in Business Standard and Nava Telangana regarding special window for re-lodgement of transfer requests of physical shares.

Company Update / Newspaper Publication View filing →

Analyst / Investor Meet - Intimation

Intimation of participation by the officials of the Company in the Investor/Analyst Meet to be held on August 11 to 13, 2026 in Singapore & Hong Kong

Company Update / Analyst / Investor Meet View filing →

Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Confirmation of dispatch of letter to the shareholders who have not registered their email ids, providing weblink for integrated Annual Report 2025-26.

Company Update / General View filing →

Newspaper Publication

Submission of copies of notice published in newspapers.

Company Update / Newspaper Publication View filing →

Reg. 34 (1) Annual Report.

Submission of Integrated Annual Report 2025-26

Others / Reg. 34 (1) Annual Report View filing →

Notice Of 39Th Annual General Meeting

Submission of Notice of 39th Annual General Meeting of the Company to be held August 27, 2026.

AGM/EGM / AGM View filing →

Business Responsibility and Sustainability Reporting (BRSR)

Submission of BRSR for FY 2025-26.

Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →

Newspaper Publication

Submission of copies of notice published in newspapers intimating the shareholders that the 39th AGM of the Company will be held on August 27, 2026.

Company Update / Newspaper Publication View filing →

Analyst / Investor Meet - Intimation

Intimation of schedule of Earnings Call to be held on August 6, 2026 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the first quarter ended June 30, 2026.

Company Update / Analyst / Investor Meet View filing →

Intimation Of 39Th Annual General Meeting Of Aurobindo Pharma Limited.

Intimation of 39th Annual General Meeting of Aurobindo Pharma Limited to be held on August 27, 2026.

AGM/EGM / AGM View filing →

Board Meeting Intimation for Intimation Of Board Meeting.

Aurobindo Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting ....

Board Meeting / Board Meeting View filing →

ANVISA Approval For Curateq Biologics' Biosimilars Manufacturing Facility

Intimation of receipt of ANVISA approval for Biosimilar manufacturing facility of Curateq Biologics Private Limited, a wholly owned subsidiary of the Company.

Company Update / General View filing →

Completion Of Transfer Of Company'S Domestic Branded Generic Pharmaceutical Formulations Products Business To Auropharm Limited, A Wholly Owned Subsidiary Of The Company

Intimation of completion of transfer of Company's domestic branded generic pharmaceutical formulations products business to Auropharm Limited, a wholly owned subsidiary of the Company.

Company Update / General View filing →

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Submission of certificate under regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended June 30, 2026.

Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

Closure of Trading Window

Intimation of closure of Trading Window

Insider Trading / SAST / Closure of Trading Window View filing →

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

Intimation of receipt of necessary approvals from US Federal Trade Commission (FTC) for the acquisition of Lannett business.

Company Update / General View filing →

Completion Of US FDA Pre-Approval Inspection (PAI) At Eugia Steriles Private Limited, A 100% Stepdown Subsidiary Of The Company

Intimation of completion of US FDA Pre-Approval Inspection (PAI) at Eugia Steriles Private Limited, a 100% stepdown subsidiary of the Company.

Company Update / General View filing →

Classification Of US FDA Inspection At Unit-III Of Eugia Pharma Specialities Limited, Pashamylaram (Our Wholly Owned Subsidiary) As OAI

Intimation of US FDA Inspection at Unit-III of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company as OAI.

Company Update / General View filing →

Newspaper Publication

Submission of notice published in the newspapers.

Company Update / Newspaper Publication View filing →

Analyst / Investor Meet - Intimation

Intimation of Participation in Investor meeting to be held on June 12, 2026

Company Update / Analyst / Investor Meet View filing →

Analyst / Investor Meet - Intimation

Intimation of Participation in Investor meeting to be held on June 10, 2026

Company Update / Analyst / Investor Meet View filing →

Analyst / Investor Meet - Intimation

Intimation of investor meeting to be held on June 8, 2026 at Mumbai

Company Update / Analyst / Investor Meet View filing →